PauseRX Review
Best for: Buyers who value **supply-chain transparency** — PauseRX's explicit disclosure of the 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) + physician network (Beluga Health) + corporate entity (PauseRX, Inc.) is significantly above the typical DTC GLP-1 platform floor and lets buyers independently verify the clinical and dispensing pipeline. Strong fit for buyers comfortable with cash-pay (no insurance), async telehealth, and the restrictive no-cancellation policy. NOT a menopause-specific platform despite the brand name — buyers seeking that focus should look at Alloy, Midi Health, or Hers Menopause.
PauseRX (pauserx.com — legal entity 'PauseRX, Inc.') is a nationwide DTC compounded GLP-1 telehealth platform with **explicit 503A pharmacy partner disclosure** (Strive Pharmacy, 275 E Baseline Rd #104, Gilbert AZ 85233) and **explicit physician-network disclosure** (Beluga Health, belugahealth.com) — both significantly above the typical DTC platform transparency floor. Verbatim FDA compounded-medication disclaimer published verbatim: 'Compounded medications, where prescribed, are patient-specific and compounded in a licensed 503(A) compounding pharmacy. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality.' Despite the 'Pause' name evoking menopause, the FAQ confirms the site is NOT formally positioned as menopause-specific — it emphasizes weight loss (GLP-1), performance (Sermorelin), longevity (NAD+), and antioxidants (Glutathione). Products: Personalized GLP-1 (contains semaglutide) at 'All doses at $199'/mo flat; Personalized GLP-1/GIP (contains tirzepatide) 'Starting at $249'/mo; brand Wegovy, Wegovy Pill, Zepbound, and Foundayo consultations also offered. LegitScript badge displayed (ID not specified in FAQ). Cancellation: 'Orders begin processing immediately after they are placed. As a result, we are unable to change or cancel them once submitted. Medications are not able to be returned or exchanged.' Billed when meds ship. Insurance NOT accepted. 18+ only. Async telehealth model with potential video/chat requirement in some states. Phone: (844) 917-2873. Email: hello@pauserx.com. NOT disclosed: state-by-state coverage list, named medical director, LegitScript ID number, HSA/FSA eligibility, corporate physical address. Live-verified 2026-05-20.
Medium confidence · Last verified 2026-05-20 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
PauseRX is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
PauseRX prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| All doses (flat) | compounded | $199 |
| Starting tier | compounded | $249 |
✓ Pros
- •**Explicit 503A pharmacy partner disclosure (Strive Pharmacy, Gilbert AZ 85233)** — genuinely uncommon. Buyers can independently verify Strive Pharmacy's licensure + 503A status. Removes the typical DTC marketplace abstraction.
- •**Explicit physician-network disclosure (Beluga Health)** — buyers can research the clinical platform handling their prescriptions. Significantly above the 'certified healthcare providers' generic-language floor.
- •**Verbatim FDA compounded-medication disclaimer published** — meets WLR transparency standard for compounded-product communication
- •**Corporate legal entity disclosed (PauseRX, Inc.)** — uncommon for DTC GLP-1 platforms
- •$199 flat 'all doses' compounded sema pricing removes per-tier escalation
- •Billing at ship (not at order) reduces upfront cash exposure
- •LegitScript badge displayed (verification posture present even if ID not numbered in FAQ)
- •Adjunct longevity products (NAD+, Glutathione, Sermorelin) for buyers seeking broader wellness stack within one platform
✗ Cons
- •**State-by-state coverage list NOT enumerated** — site claims nationwide but specific state availability requires contacting support
- •**Cancellation policy is restrictive: 'unable to change or cancel once submitted. Medications are not able to be returned or exchanged.'** — buyers who change their mind after placing an order have no recourse
- •**Named medical director / clinical lead NOT disclosed** by name despite Beluga Health network disclosure (Beluga is the network, not a named MD)
- •**LegitScript ID NUMBER not specified in FAQ** — badge is displayed but the verifiable certification number is not surfaced, preventing direct lookup
- •Insurance NOT accepted — cash-pay only
- •HSA/FSA eligibility NOT confirmed in FAQ
- •Corporate physical address NOT provided (only Strive Pharmacy + Beluga Health addresses)
- •Despite the 'Pause' brand name, the platform is NOT formally positioned as menopause/perimenopause-specific — buyers seeking menopause-focused clinical care should look at dedicated menopause platforms
- •Brand Wegovy + Zepbound + Foundayo are 'consultations' (not direct dispensing) — fulfillment depends on the brand-drug supply chain elsewhere
Ready to start with PauseRX?
Starting at $199/month. See current pricing and start your free consultation.
Sources & methodology
Our PauseRX review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to PauseRX
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with PauseRX?
Starting at $199/month. See current pricing and start your free consultation.